Publications by authors named "D M Systrom"
Introduction: Despite shared features with pulmonary arterial hypertension, acute vasoreactivity in pulmonary hypertension with interstitial lung disease (PH-ILD) is not well characterised, including its potential ability to predict therapeutic outcomes. We sought to determine whether acute vasoreactivity in PH-ILD to oxygen (O) and inhaled nitric oxide (iNO) predicts inhaled treprostinil (iTre) outcomes.
Materials And Methods: In this retrospective cohort analysis, we identified treatment-naive PH-ILD patients with vasoreactivity testing using O and O+iNO.
Background: Exercise pulmonary hypertension (PH) was defined by a mean pulmonary arterial pressure (mPAP)/cardiac output (CO) slope >3 mmHg·min·L between rest and exercise in the 2022 European Society of Cardiology/European Respiratory Society PH guidelines. However, large, multicentre studies on the prognostic relevance of exercise haemodynamics and its added value to resting haemodynamics are missing.
Patients And Methods: The PEX-NET (Pulmonary Haemodynamics during Exercise Network) registry enrolled patients who underwent clinically indicated right heart catheterisations both at rest and ergometer exercise from 23 PH centres worldwide.
Background: Spectrum of chronic orthostatic intolerance without orthostatic hypotension includes postural tachycardia syndrome (POTS), with orthostatic tachycardia and hypocapnic cerebral hypoperfusion (HYCH), without orthostatic tachycardia. This study compared autonomic, cerebrovascular, and neuropathic features of POTS and HYCH.
Methods: This retrospective study evaluated patients with orthostatic intolerance referred for autonomic testing.
Article Synopsis
- - This study evaluated the effects of sotatercept on exercise tolerance, capacity, and right ventricular function in patients with pulmonary arterial hypertension through the SPECTRA clinical trial.
- - Results showed that out of 21 participants, there was a significant increase in peak oxygen uptake after 24 weeks of treatment, along with improvements in exercise hemodynamics and walking distance.
- - The findings suggest that sotatercept could be a promising new treatment option for pulmonary arterial hypertension, potentially reversing heart function decline.